Multidisciplinary Surgical Team Approach Improves OS in Ovarian Cancer
November 1st 2023After implementing a multidisciplinary surgical approach, researchers found that use of the new approach, residual disease, and age were all independent predictors of overall and progression-free survival for patients with ovarian cancer.
Read More
Improved PFS in Advanced Ovarian Cancer With Senaparib vs Placebo
October 31st 2023The phase 3 FLAMES trial results demonstrated an improvement in progression-free survival with senaparib monotherapy vs placebo, regardless of patient subgroup, in patients with newly diagnosed, advanced ovarian cancer.
Read More
Triplet Maintenance Therapy Effective in Platinum-Sensitive Recurrent Ovarian Cancer
October 31st 2023Results from the OPEB-01/APGOT-OV4 trial highlight the potential benefits of using olaparib, pembrolizumab, and bevacizumab as a triplet maintenance therapy for patients who have responded to chemotherapy after experiencing platinum-sensitive recurrence in ovarian cancer.
Read More
The European Medicines Agency (EMA) has accepted a marketing authorization application seeking the approval of mirvetuximab soravtansine-gynx for the treatment of patients with folate receptor alpha–positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Read More
FDA Grants Fast Track Designation to IDE161 for BRCA+, Platinum-Resistant Advanced Ovarian Cancer
September 30th 2023The FDA has granted fast track designation to IDE161 for the treatment of adult patients with advanced or metastatic ovarian cancer harboring germline or somatic BRCA1/2 mutations who are platinum resistant and have received prior treatment with antiangiogenic and poly-ADP ribose polymerase, or PARP, inhibitor therapies.
Read More
Atezolizumab Misses PFS End Point in Recurrent Epithelial Ovarian Cancer
September 12th 2023Results from ATLANTE/ENGOT-ov29 show that atezolizumab did not significantly improve progression-free survival (PFS) compared with placebo plus bevacizumab for patients with platinum-sensitive ovarian cancer.
Read More
TTFields Plus Paclitaxel Misses OS End Point in Platinum-Resistant Ovarian Cancer
September 9th 2023The phase 3 ENGOT-ov50/GOG-3029/INNOVATE-3 trial found the addition of tumor treating fields (TTFields) to paclitaxel did not provide a statistically significant improvement in overall survival (OS) vs paclitaxel alone for patients with platinum-resistant ovarian cancer, failing to meet its primary end point.
Read More
Study Highlights Factors Linked to ED Readmission Following Ovarian Carcinoma Surgery
September 6th 2023Out of several factors, surgical complications were the only factor independently associated with emergency department (ED) readmission among patients who underwent surgery for ovarian carcinoma.
Read More
The platinum drugs most effective in treating ovarian cancer are in limited supply due to the drug shortage; the government proposes a plan to prevent hospitals from redistributing Medicaid money; physicians ask for help in treating the high number of children with mental illness coming to the emergency department.
Read More
Exercise May Reduce Chemotherapy-Induced Peripheral Neuropathy Symptoms in Women With Ovarian Cancer
August 9th 2023While there is currently no effective treatment for chemotherapy-induced peripheral neuropathy, one of the most common and severe adverse effects for patients who have undergone chemotherapy for ovarian cancer, a 6-month aerobic exercise intervention significantly improved symptoms.
Read More
Niraparib Maintenance Therapy Improves PFS by 55% in Advanced Ovarian Cancer
August 2nd 2023Results of the phase 3 PRIME study showed that treatment with niraparib with an individualized starting dose significantly extended progression-free survival (PFS) and reduced the risk of disease progression or death by 55% compared with placebo.
Read More